

.....  
(Original Signature of Member)

115TH CONGRESS  
1ST SESSION

**H. R.** \_\_\_\_\_

To protect the public health by providing the Food and Drug Administration with certain authority to regulate e-liquids and personal electronic vaporizers, to reduce the morbidity and mortality resulting from cigarette smoking through the responsible regulation of e-liquids and personal electronic vaporizers as a tobacco harm reduction strategy, and for other purposes.

\_\_\_\_\_  
IN THE HOUSE OF REPRESENTATIVES

Mr. HUNTER introduced the following bill; which was referred to the  
Committee on \_\_\_\_\_

\_\_\_\_\_  
**A BILL**

To protect the public health by providing the Food and Drug Administration with certain authority to regulate e-liquids and personal electronic vaporizers, to reduce the morbidity and mortality resulting from cigarette smoking through the responsible regulation of e-liquids and personal electronic vaporizers as a tobacco harm reduction strategy, and for other purposes.

1       *Be it enacted by the Senate and House of Representa-*  
2       *tives of the United States of America in Congress assembled,*

1 **SECTION 1. SHORT TITLE; TABLE OF CONTENTS.**

2 (a) SHORT TITLE.—This Act may be cited as the  
3 “Cigarette Smoking Reduction and Electronic Vapor Al-  
4 ternatives Act of 2017”.

5 (b) TABLE OF CONTENTS.—The table of contents of  
6 this Act is as follows:

Sec. 1. Short title; table of contents.

Sec. 2. Findings.

Sec. 3. Purposes of the Family Smoking Prevention and Tobacco Control Act.

Sec. 4. Regulation of electronic vapor products.

Sec. 5. Joint comparative health risk assessment.

7 **SEC. 2. FINDINGS.**

8 The Congress finds the following:

9 (1) Cigarette smoking is the practice of burning  
10 tobacco rolled in a paper and inhaling the smoke.  
11 According to the Department of Health and Human  
12 Services—

13 (A) the burning of tobacco produces a  
14 chemical mixture of more than 7,000 com-  
15 pounds;

16 (B) cigarette smoking causes cancer, heart  
17 disease, stroke, lung diseases, diabetes, and  
18 chronic obstructive pulmonary disease, and  
19 harms nearly every organ of the body;

20 (C) cigarette smoking causes more than  
21 480,000 deaths each year, including nearly  
22 42,000 deaths due to secondhand tobacco  
23 smoke;

1 (D) the economic cost of cigarette smoking  
2 is more than \$300 billion a year, including  
3 nearly \$170 billion in direct medical care, and  
4 more than \$156 billion in lost productivity; and

5 (E) nearly 7 in 10 adult cigarette smokers  
6 want to quit smoking.

7 (2) Electronic vapor products, also known as  
8 “electronic cigarettes” or “e-cigarettes”, are battery-  
9 operated devices that use low heat to turn e-liquid,  
10 which generally contains nicotine, into a vaporized  
11 aerosol which is inhaled—there is no burning of to-  
12 bacco or generation of smoke for inhalation.

13 (3) Evidence from numerous studies strongly  
14 suggests that electronic vapor products are mag-  
15 nitudes safer than traditional, combustible ciga-  
16 rettes. Studies have found that several million reg-  
17 ular vapers in the United States no longer regularly  
18 smoke cigarettes.

19 (4) Studies of cigarette smokers who switched  
20 to vapor found significant improvements in lung  
21 function, including a study finding asthmatic smok-  
22 ers who switched to vapor had significant improve-  
23 ments in spirometry data, asthma control, airway  
24 hyperresponsiveness, and lower blood pressure.

1           (5) The Royal College of Physicians 2016 re-  
2           port on e-cigarettes titled, “Nicotine without smoke:  
3           Tobacco harm reduction” issued the following find-  
4           ings:

5                   (A) The available evidence to date indi-  
6                   cates that e-cigarettes are being used almost ex-  
7                   clusively as safer alternatives to smoked to-  
8                   bacco, by confirmed smokers who are trying to  
9                   reduce harm to themselves or others from  
10                  smoking, or to quit smoking completely.

11                  (B) The hazard to health arising from  
12                  long-term vapor inhalation from the e-cigarettes  
13                  available today is unlikely to exceed 5 percent  
14                  of the harm from smoking tobacco.

15                  (C) E-cigarettes are marketed as consumer  
16                  products and are proving much more popular  
17                  than Food and Drug Administration-approved  
18                  nicotine replacement therapies (NRT) as a sub-  
19                  stitute and competitor for tobacco cigarettes.

20           (6) “E-Liquid” is the liquid that is heated into  
21           vapor. It contains, principally, propylene glycol, veg-  
22           etable glycerin, in some cases food flavoring, in some  
23           cases nicotine, and in some cases water; propylene  
24           glycol and vegetable glycerin are designated as “gen-

1 erally recognized as safe” by the Food and Drug Ad-  
2 ministration (FDA) as food additives.

3 (7) Surveys have found that a significant ma-  
4 jority of regular users of electronic vapor products  
5 had previously tried FDA-approved smoking ces-  
6 sation drugs to quit smoking without success.

7 (8) An expert independent evidence review pub-  
8 lished by Public Health England (PHE) concluded  
9 that—

10 (A) the use of vapor products is about 95  
11 percent less harmful than cigarette smoking;

12 (B) nearly half the population doesn’t real-  
13 ize vapor is much less harmful than smoking;  
14 and

15 (C) there is no evidence suggesting elec-  
16 tronic vapor products act as a route into smok-  
17 ing for children or nonsmokers.

18 (9) Electronic vapor product sales in the United  
19 States have increased from an estimated \$100 mil-  
20 lion in 2010 to \$3.5 billion in 2015 while cigarette  
21 consumption in the United States declined from  
22 \$307 billion in 2010 to an estimated \$265 billion in  
23 2015.

24 (10) On May 10, 2016 the Food and Drug Ad-  
25 ministration issued its “Deeming Regulation” to

1        deem e-cigarettes or electronic vapor products to be  
2        subject to its authority. The regulation will, as a  
3        practical matter, because of its significant compli-  
4        ance costs and poorly articulated standard for pro-  
5        tecting public health, ban the sale of all electronic  
6        vapor products by August 2018.

7            (11) The Food and Drug Administration's  
8        Deeming Regulation, by effectively banning elec-  
9        tronic vapor products, will push vapers who have  
10       quit or reduced cigarette smoking by switching to  
11       electronic vapor products back to smoking deadly  
12       cigarettes.

13           (12) The 2015 Monitoring the Future survey of  
14       the National Institute on Drug Abuse found past-  
15       30-day use of an electronic vapor product by 8th,  
16       10th, and 12th graders combined declined from 13.9  
17       percent in 2014 to 13.2 percent in 2015; however,  
18       that survey found that fewer than 20 percent of  
19       teens who used an electronic vapor product in the  
20       past 30 days reported using a product containing  
21       nicotine.

22           (13) Electronic vapor products show tremen-  
23       dous promise in reducing cigarette smoking, and cig-  
24       arette smoking attributable morbidity, mortality,  
25       and health care costs.

1           (14) Since the Food and Drug Administration  
2           was granted authority to regulate tobacco products  
3           in 2009, the agency has failed to grant market ap-  
4           proval to any modified risk tobacco product.

5   **SEC. 3. PURPOSES OF THE FAMILY SMOKING PREVENTION**  
6                           **AND TOBACCO CONTROL ACT.**

7           Section 3 of the Family Smoking Prevention and To-  
8           bacco Control Act (21 U.S.C. 387 note) is amended by  
9           amending paragraph (9) to read as follows:

10                   “(9) to promote—

11                           “(A) cessation to reduce disease risk and  
12                           the social costs associated with tobacco-related  
13                           diseases; and

14                           “(B) harm reduction strategies; and”.

15   **SEC. 4. REGULATION OF ELECTRONIC VAPOR PRODUCTS.**

16           (a) CENTER FOR TOBACCO PRODUCTS AND TOBACCO  
17           HARM REDUCTION.—Section 901(e) of the Federal Food,  
18           Drug, and Cosmetic Act (21 U.S.C. 387a(e)) is amend-  
19           ed—

20                   (1) in the subsection heading, by striking  
21                   “CENTER FOR TOBACCO PRODUCTS” and inserting  
22                   “CENTER FOR TOBACCO PRODUCTS AND TOBACCO  
23                   HARM REDUCTION”;

1           (2) by striking “Center for Tobacco Products”  
2           and inserting “Center for Tobacco Products and To-  
3           bacco Harm Reduction”; and

4           (3) by striking “this chapter” and inserting  
5           “this chapter and chapter X”.

6           (b) FDA AUTHORITY OVER ELECTRONIC VAPOR  
7           PRODUCTS.—

8           (1) EXCLUSION FROM DEFINITION OF TOBACCO  
9           PRODUCT.—Section 201(rr) of the Federal Food,  
10          Drug, and Cosmetic Act (21 U.S.C. 321(rr)) is  
11          amended—

12                 (A) in paragraph (2), by inserting “an e-  
13                 liquid (as defined in section 1001), a personal  
14                 electronic vaporizer (as defined in section  
15                 1001),” before “or a combination product”; and

16                 (B) in paragraph (3), by inserting after  
17                 “The products described in paragraph (2)” the  
18                 following: “(other than an e-liquid or personal  
19                 electronic vaporizer)”.

20          (2) COMBINATION PRODUCTS.—Section 503(g)  
21          of the Federal Food, Drug, and Cosmetic Act (21  
22          U.S.C. 353(g)) is amended—

23                 (A) in paragraph (1)—

24                         (i) in subparagraph (A), by striking  
25                         “or biological product” and inserting “, bi-



1                   logical product, e-liquid, or personal elec-  
2                   tronic vaporizer”; and

3                   (ii) in subparagraph (D)—

4                   (I) in clause (ii), by striking “or”  
5                   at the end;

6                   (II) in clause (iii), by striking the  
7                   period at the end and inserting “; or”;  
8                   and

9                   (III) by adding at the end the  
10                  following:

11                 “(iv) an e-liquid or personal electronic vapor-  
12                 izer, the agency center charged with regulating e-liq-  
13                 uids and personal electronic vaporizers shall have  
14                 primary jurisdiction.”; and

15                 (B) in paragraph (9)—

16                 (i) by redesignating subparagraphs  
17                 (C) and (D) as subparagraphs (D) and  
18                 (E), respectively; and

19                 (ii) by inserting after subparagraph  
20                 (B) the following:

21                 “(C) The terms ‘e-liquid’ and ‘personal elec-  
22                 tronic vaporizer’ have the meanings given to such  
23                 terms in section 1001.”.

1           (3) REGULATORY AUTHORITY.—The Federal  
2 Food, Drug, and Cosmetic Act (21 U.S.C. 301 et  
3 seq.) is amended—

4           (A) by redesignating chapter X as chapter  
5 XI;

6           (B) by redesignating sections 1001  
7 through 1014 as sections 1101 through 1114,  
8 respectively;

9           (C) in section 505(n)(2), by striking  
10 “1004” and inserting “1104”;

11           (D) in sections 523(b)(2)(D) and  
12 704(g)(13), by striking “1003(g)” and inserting  
13 “1103(g)”;

14           (E) in section 1109(a)(5)(A), as redesign-  
15 nated by paragraph (4), by striking “1008”  
16 and inserting “1108”; and

17           (F) by inserting after chapter IX the fol-  
18 lowing:

19           **“CHAPTER X—ELECTRONIC VAPOR**  
20                                   **PRODUCTS**

21           **“SEC. 1001. DEFINITIONS.**

22           “In this chapter:

23                   “(1) The term ‘e-liquid’ means any liquid solu-  
24 tion that—

25                                   “(A) may or may not contain nicotine; and

1           “(B) is intended to be converted into an  
2           aerosol, vapor, or vapor-like mist for users to  
3           inhale through the mouthpiece of a personal  
4           electronic vaporizer.

5           “(2) The term ‘personal electronic vaporizer’  
6           means an electronic device that employs a heating  
7           element or atomizer that converts an e-liquid into an  
8           aerosol, vapor, or vapor-like mist through a non-  
9           combustive process.

10           “(3) The terms ‘e-liquid’ and ‘personal elec-  
11           tronic vaporizer’ exclude—

12                   “(A) a drug as defined in section  
13                   201(g)(1);

14                   “(B) a device as defined in section 201(h);  
15                   and

16                   “(C) a biological product as defined in sec-  
17                   tion 351 of the Public Health Service Act.

18   **“SEC. 1002. EXCLUSIVE AUTHORITY FOR REGULATING E-  
19                   LIQUIDS AND PERSONAL ELECTRONIC VA-  
20                   PORIZERS.**

21           “The authorities vested by this chapter constitute the  
22           exclusive authorities of the Secretary to regulate e-liquids  
23           and personal electronic vaporizers, except to the extent e-  
24           liquids and personal electronic vaporizers are within com-  
25           bination products regulated pursuant to section 503(g).

1 **“SEC. 1003. PROHIBITED ACTS; PENALTIES.**

2 “(a) PROHIBITIONS.—The following acts and the  
3 causing thereof are hereby prohibited:

4 “(1) The manufacture of an e-liquid or personal  
5 electronic vaporizer in noncompliance with the  
6 standards under section 1004(b) in violation of an  
7 order issued under section 1004(e).

8 “(2) The offering of e-liquids or personal elec-  
9 tronic vaporizers for sale in interstate commerce by  
10 an e-liquid or personal electronic vaporizer manufac-  
11 turer that does not have a certification in effect as  
12 required by section 1004(e).

13 “(3) The failure by an e-liquid or personal elec-  
14 tronic vaporizer manufacturer to provide access for  
15 inspection as required by section 1004(d).

16 “(4)(A) The introduction or delivery for intro-  
17 duction in interstate commerce of an e-liquid or per-  
18 sonal electronic vaporizer by any person that is adul-  
19 terated or misbranded, as described in subsection (b)  
20 or (c) respectively.

21 “(B) Notwithstanding subparagraph (A), a re-  
22 tailer may be found to be in violation of such sub-  
23 paragraph with respect to the introduction or deliv-  
24 ery for introduction in interstate commerce of an e-  
25 liquid or personal electronic vaporizer at retail only  
26 if the violation occurs knowingly.

1       “(b) ADULTERATION.—An e-liquid or personal elec-  
2 tronic vaporizer shall be treated as adulterated if—

3           “(1) it was manufactured in noncompliance  
4 with the standards under section 1004(b) in viola-  
5 tion of an order issued under section 1004(e); or

6           “(2) it was manufactured by an e-liquid or per-  
7 sonal electronic vaporizer manufacturer that does  
8 not have a certification in effect as required by sec-  
9 tion 1004(c).

10       “(c) MISBRANDING.—An e-liquid or personal elec-  
11 tronic vaporizer shall be treated as misbranded if its label-  
12 ing (as such term is defined in section 201 with respect  
13 to drugs) is in noncompliance with the standards under  
14 section 1004(b) in violation of an order issued under sec-  
15 tion 1004(e).

16       “(d) PENALTIES.—An e-liquid or personal electronic  
17 vaporizer manufacturer who violates a provision of sub-  
18 section (a) shall be imprisoned not more than 3 years,  
19 fined not more than \$10,000 (notwithstanding section  
20 3571(e) of title 18, United States Code) for each day on  
21 which the violation continues, or both.

1 **“SEC. 1004. STANDARDS FOR THE MANUFACTURING OF E-**  
2 **LIQUIDS AND PERSONAL ELECTRONIC VA-**  
3 **PORIZERS; COMPLIANCE.**

4 “(a) REQUIREMENT.—Beginning on the date that is  
5 1 year after the date of enactment of the Cigarette Smok-  
6 ing Reduction and Electronic Vapor Alternatives Act of  
7 2017, any e-liquid or personal electronic vaporizer intro-  
8 duced or delivered for introduction into interstate com-  
9 merce shall conform to the e-liquid or personal electronic  
10 vaporizer (as applicable) manufacturing standards under  
11 subsection (b), including the labeling standards therein.

12 “(b) MANUFACTURING STANDARDS.—

13 “(1) E-LIQUIDS.—The manufacturing stand-  
14 ards for e-liquids under this subsection shall consist  
15 of the following:

16 “(A) INTERIM STANDARDS.—The e-liquid  
17 manufacturing standards issued by the Amer-  
18 ican E-Liquid Manufacturing Standards Asso-  
19 ciation (version 2.3.) on January 13, 2016 (in-  
20 cluding any revision to such standards made in  
21 accordance with paragraph (3)) apply to the in-  
22 troduction or delivery for introduction into  
23 interstate commerce of e-liquids during the pe-  
24 riod beginning on the date described in sub-  
25 section (a) and ending on the date described in  
26 subparagraph (B).

1           “(B) SUBSEQUENT STANDARDS.—The e-  
2           liquid manufacturing standards of the American  
3           National Standards Institute (including any re-  
4           vision to such standards made in accordance  
5           with paragraph (3)) apply to the introduction  
6           or delivery for introduction into interstate com-  
7           merce of e-liquids beginning on the date of the  
8           adoption of such standards by the American  
9           National Standards Institute.

10          “(2) PERSONAL ELECTRONIC VAPORIZERS.—  
11          The manufacturing standards for personal electronic  
12          vaporizers under this subsection shall consist of the  
13          following:

14                 “(A) BATTERY SAFETY.—Any battery used  
15                 in a personal electronic vaporizer shall conform  
16                 to the IEC 62133 standards of the Inter-  
17                 national Electrotechnical Commission, as in ef-  
18                 fect on the date of enactment of the Cigarette  
19                 Smoking Reduction and Electronic Vapor Alter-  
20                 natives Act of 2017 and including any revision  
21                 to such standards made in accordance with  
22                 paragraph (3).

23                 “(B) SHORT CIRCUIT PROTECTION.—A  
24                 personal electronic vaporizer shall have a mech-

1           anism to ensure user and battery safety in the  
2           event of a short circuit of the heating element.

3           “(C) DISCHARGE MONITORING.—A re-  
4           chargeable personal electronic vaporizer shall  
5           have a mechanism to prevent the battery from  
6           being discharged below a safe voltage during  
7           use or discharged faster than the battery can  
8           sustain safely.

9           “(D) CHARGE MONITORING.—A personal  
10          electronic vaporizer that contains an onboard  
11          charger shall include circuitry to monitor the  
12          battery voltage and charge current and limit  
13          these to safe levels. A personal electronic vapor-  
14          izer that contains multiple battery cells in series  
15          shall monitor the cells individually.

16          “(E) SERIAL AND LOT NUMBERS.—A per-  
17          sonal electronic vaporizer shall include a serial  
18          or lot number on the label that allows the va-  
19          porizer to be traced to its time and place of  
20          manufacture. Notwithstanding the preceding  
21          sentence, a single-use personal electronic vapor-  
22          izer may have such serial or lot number on the  
23          packaging of the vaporizer other than the label.

24          “(F) VERIFICATION AND VALIDATION.—A  
25          personal electronic vaporizer shall be con-



1           structured with sufficiently validated processes, or  
2           subject to sufficient verification and testing, to  
3           ensure that each individual vaporizer conforms  
4           to its specifications.

5           “(G) TRACKING AND RECALLS.—The man-  
6           ufacturer of a personal electronic vaporizer  
7           shall record all shipments of one or more per-  
8           sonal electronic vaporizers by the manufacturer  
9           to a distributor, retailer, or end user, and cor-  
10          relate each such shipment to serial or lot num-  
11          bers, to enable batch tracking and recalls.

12          “(H) MATERIALS.—The manufacturer of a  
13          personal electronic vaporizer shall ensure that—

14               “(i) materials that come in contact  
15               with e-liquids or vapor during manufacture  
16               or reasonably foreseeable use of the per-  
17               sonal electronic vaporizer are limited to ap-  
18               proved medical or food contact grade prod-  
19               ucts with established safety and biocompat-  
20               ibility characteristics; and

21               “(ii) components of a personal elec-  
22               tronic vaporizer which are expected to be  
23               subject to heat are appropriate for the ex-  
24               pected temperatures.

1           “(3) REVISIONS.—Before issuing a revision to  
2           the standards applicable under paragraph (1)(A),  
3           (1)(B), or (2)(A), the American E–Liquid Manufac-  
4           turing Standards Association, the American Na-  
5           tional Standards Institute, or the International Elec-  
6           trotechnical Commission, as applicable, shall notify  
7           the Secretary in writing of the proposed revision.  
8           Not later than 90 days after the date of receipt of  
9           such notice, the Secretary shall determine whether  
10          the proposed revision enhances the safety and qual-  
11          ity of e-liquid products or personal electronic vapor-  
12          izers, as applicable. If the Secretary determines that  
13          the proposed revision does enhance the safety and  
14          quality of e-liquid products or personal electronic va-  
15          porizers, as applicable, the Secretary shall give no-  
16          tice of such determination to the public for a period  
17          of 90 days and, effective at the end of such period,  
18          incorporate the revision into the standards applicable  
19          under paragraph (1)(A), (1)(B), or (2)(A), as appli-  
20          cable.

21          “(c) CERTIFICATION OF COMPLIANCE WITH MANU-  
22          FACTURING STANDARDS.—Beginning not later than 1  
23          year after the date of enactment of the Cigarette Smoking  
24          Reduction and Electronic Vapor Alternatives Act of 2017,  
25          each e-liquid and personal electronic vaporizer manufac-

1 turer offering e-liquids for sale in interstate commerce  
2 shall have in effect a certification filed with the Secretary  
3 in writing that all such e-liquids or personal electronic va-  
4 porizers, as applicable, are manufactured, labeled, and  
5 otherwise in compliance with the standards under sub-  
6 section (b).

7 “(d) INSPECTIONS FOR COMPLIANCE WITH MANU-  
8 FACTURING STANDARDS.—E-liquid and personal elec-  
9 tronic vaporizer manufacturers shall provide the Secretary  
10 with access to their facilities used in manufacturing e-liq-  
11 uids or personal electronic vaporizers, as applicable, for  
12 inspection.

13 “(e) FAILURE TO COMPLY WITH MANUFACTURING  
14 STANDARDS.—

15 “(1) IN GENERAL.—If the Secretary finds that  
16 an e-liquid or personal electronic vaporizer manufac-  
17 turer is in noncompliance with the standards under  
18 subsection (b)—

19 “(A) the Secretary shall not take any en-  
20 forcement action based on such noncompliance  
21 unless—

22 “(i) the Secretary gives the manufac-  
23 turer notice of, and a period of 90 days to  
24 correct, such noncompliance; and

1                   “(ii) the manufacturer fails, by the  
2                   end of such 90-day period, to correct such  
3                   noncompliance; and

4                   “(B) if the manufacturer fails to correct  
5                   such noncompliance, as described in paragraph  
6                   (1)(A)(ii), the Secretary may issue an order re-  
7                   quiring the manufacturer—

8                   “(i) to suspend any commercial activ-  
9                   ity that the Secretary finds to be in non-  
10                  compliance; and

11                  “(ii) to not resume such activity until  
12                  the manufacturer demonstrates to the Sec-  
13                  retary’s satisfaction that such noncompli-  
14                  ance has been corrected.

15                  “(2) IMMEDIATE DANGER TO PUBLIC  
16                  HEALTH.—Notwithstanding paragraph (1), if the  
17                  Secretary determines that an e-liquid or personal  
18                  electronic vaporizer manufacturer is in noncompli-  
19                  ance with the standards under subsection (b), and  
20                  that such noncompliance presents an immediate dan-  
21                  ger to public health, the Secretary may issue an  
22                  order requiring the manufacturer to suspend produc-  
23                  tion of such e-liquid or personal electronic vaporizer  
24                  until the Secretary determines that such noncompli-  
25                  ance is corrected.

1 **“SEC. 1005. PROHIBITION AGAINST ADVERTISING OR PRO-**  
2 **MOTING TO MINORS.**

3 “(a) PROHIBITION.—The Secretary may by regula-  
4 tion prohibit any manufacturer of an e-liquid or personal  
5 electronic vaporizer from advertising or promoting the e-  
6 liquid or personal electronic vaporizer to individuals who  
7 have not attained 18 years of age.

8 “(b) PENALTY.—If a manufacturer violates a prohi-  
9 bition established under subsection (a), the Secretary may  
10 refuse to accept for filing or renewal, and may revoke, the  
11 manufacturer’s certification under section 1004(c).

12 **“SEC. 1006. PREEMPTION OF CERTAIN STATE AND LOCAL**  
13 **REQUIREMENTS.**

14 “(a) IN GENERAL.—No State or political subdivision  
15 of a State may establish or continue in effect any require-  
16 ment with respect to the manufacture, distribution, or sale  
17 of an e-liquid or personal electronic vaporizer which is dif-  
18 ferent from, or in addition to, any requirement under the  
19 provisions of this chapter or pursuant to section 503(g),  
20 including the exclusion of e-liquids and personal electronic  
21 vaporizers from the definition of a tobacco product under  
22 section 201.

23 “(b) EXCEPTION.—Information disclosed to a State  
24 consistent with subsection (a) that is exempt from disclo-  
25 sure under section 552(b)(4) of title 5, United States

1 Code, shall be treated as a trade secret and confidential  
2 information by the State.

3 **“SEC. 1007. OFFICE FOR E-LIQUID AND PERSONAL ELEC-**  
4 **TRONIC VAPORIZER STANDARDS COMPLI-**  
5 **ANCE.**

6 “Not later than 90 days after the date of enactment  
7 of the Cigarette Smoking Reduction and Electronic Vapor  
8 Alternatives Act of 2017, the Secretary shall establish  
9 within the Food and Drug Administration’s Center for To-  
10 bacco Products and Tobacco Harm Reduction an Office  
11 of E–Liquid and Personal Electronic Vaporizer Standards  
12 Compliance. The Office shall—

13 “(1) be responsible for the implementation of  
14 this chapter and related matters assigned by the Di-  
15 rector of such Center; and

16 “(2) provide technical and other nonfinancial  
17 assistance to e-liquid and personal electronic vapor-  
18 izer manufacturers to assist them in complying with  
19 the requirements of this Act.”.

20 **SEC. 5. JOINT COMPARATIVE HEALTH RISK ASSESSMENT.**

21 Chapter X of the Federal Food, Drug, and Cosmetic  
22 Act, as added by section 4, is further amended by adding  
23 at the end the following:

1 **“SEC. 1008. TOBACCO PRODUCTS AND NICOTINE DELIVERY**  
2 **ALTERNATIVES: COMPARATIVE HEALTH RISK**  
3 **ASSESSMENT.**

4 “(a) ASSESSMENT.—The Secretary shall undertake a  
5 tobacco products and other nicotine delivery alternatives  
6 comparative health risk assessment and rank each cat-  
7 egory of products on a scale according to the reasonable  
8 expectation for morbidity and mortality risk when com-  
9 pared to smoking cigarettes based on laboratory studies  
10 and existing scientific data. For purposes of such assess-  
11 ment, tobacco and nicotine delivery alternative product  
12 categories shall include at a minimum—

13 “(1) cigarettes;

14 “(2) loose tobacco for roll-your-own tobacco  
15 products;

16 “(3) little cigars;

17 “(4) cigars;

18 “(5) pipe tobacco;

19 “(6) moist snuff;

20 “(7) dry snuff;

21 “(8) chewing tobacco;

22 “(9) snus;

23 “(10) vaporized tobacco, meaning ‘heat not  
24 burn’ technology intended for inhalation;

25 “(11) vapor produced by a personalized elec-  
26 tronic vaporizer containing e-liquid with nicotine;

1           “(12) shish and other tobacco products that are  
2           heated and inhaled via a hookah, water pipe, or  
3           other type of pipe (treated collectively as a single  
4           category);

5           “(13) dissolvable, chewable, drinkable, and  
6           other tobacco and nicotine products intended for oral  
7           ingestion (treated collectively as a single category);

8           “(14) tobacco and nicotine skin creams, patch-  
9           es, and other tobacco and nicotine products intended  
10          for transdermal consumption (treated collectively as  
11          a single category);

12          “(15) tobacco and nicotine sprays, droplets, and  
13          mists intended for nasal consumption (treated as a  
14          single category); and

15          “(16) other nicotine-containing products (treat-  
16          ed collectively as a single category).

17          “(b) REPORT.—Not later than 18 months after the  
18          date of enactment of the Cigarette Smoking Reduction  
19          and Electronic Vapor Alternatives Act of 2017, the Sec-  
20          retary shall report to the Committee on Energy and Com-  
21          merce of the House of Representatives and the Committee  
22          on Health, Education, Labor, and Pensions of the Senate  
23          on the results of the comparative health risk assessment  
24          under subsection (a). Based on such results, such report  
25          shall include recommendations on—



1           “(1) new or improved tobacco harm reduction  
2 strategies; and  
3           “(2) the possible need for additional legislative  
4 authorities to implement such strategies.”.